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Abstract
Background: Subjects with metabolic syndrome (MetS) exhibit impaired lipoprotein metabolism and have an
increased risk of cardiovascular disease. Although the risk is attributed primarily to the risk associated with individual
components, it is also likely affected by other associated metabolic defects. Remnants of postprandial lipoproteins
show potent atherogenicity in cell and animal models of insulin resistance and in pre-diabetic subjects with
postprandial dyslipidemia. However, few studies have considered regulation of chylomicron remnant homeostasis in
MetS per se. This study measured the plasma concentration in Caucasian men and women of small dense
chylomicrons following fasting and explored associations with metabolic and anthropometric measures.
Methods: A total of 215 Australian Caucasian participants (median age 62 years) were investigated. Of them, 40
participants were classified as having MetS. Apolipoprotein (apo) B-48, an exclusive marker of chylomicrons,
metabolic markers and anthropometric measures were determined following an overnight fast.
Results: The fasting apo B-48 concentration was 40 % higher in subjects with MetS than those without MetS. In all
subjects, triglyceride (r = 0.445, P < 0.0005), non-HDL cholesterol (r = 0.28, P < 0.0005) and HDL cholesterol concentration
(r = −0.272, P < 0.0005) were weakly associated with apo B-48 concentration. In subjects with MetS, the association of
apo B-48 with triglyceride and non-HDL cholesterol was enhanced, but neither were robust markers of elevated apo
B-48 in MetS (r = 0.618 and r = 0.595 respectively). There was no association between apo B-48 and HDL cholesterol
in subjects with MetS.
Conclusion: This study demonstrates a substantial accumulation of pro-atherogenic remnants in subjects with
MetS. We have shown that in a Caucasian cohort, the fasting plasma concentration of triglyceride or HDL/non-HDL
cholesterol serves as poor surrogate markers of atherogenic chylomicron remnants. These findings suggest that subjects
with MetS exhibit a chronic defect in chylomicron metabolism that is likely to contribute to their increased CV risk.
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Background
It is recognised that patients with metabolic syndrome
(MetS) are at risk developing CVD [1–3]. Increased plasma
triglyceride and decreased HDL cholesterol are important
components of MetS syndrome, however subjects with
MetS are otherwise typically normocholesterolemic.
A substantial body of evidence supports the con-
tention that hydrolysed remnants of postprandial
chylomicrons are highly atherogenic [4, 5]. Apo B-48
concentration, a unique marker of chylomicron
particles, is associated with atherosclerosis and coron-
ary artery disease [4, 6, 7]. The presence of apo B-48
containing particles in rabbit and human atheroscler-
otic tissue [8–10] suggests that post-hydrolyzed
chylomicron remnants are an important risk for devel-
opment of atheroma. It was previously thought that
chylomicrons are synthesized and released by the
intestine only after dietary fat ingestion and that they
are primarily found in lipid-rich lipoprotein fractions.
However, we and others have reported the presence of
chylomicron particles in more dense, lipid-poor lipopro-
tein fractions in the absence of dietary fat availability
[11–13]. Small sized (remnant) chylomicron particles
are able to penetrate the arterial wall and get trapped
within the subendothelial space [14, 15]. This can cause
lipid accumulation in macrophages, a hallmark of early
atherogenesis, without prior chylomicron remnant oxi-
dative modification [16, 17].
Subjects with MetS have been found to have greater
fasting concentrations of apo B-48 [18–20]. However
these observations have been made in a Japanese popu-
lation and hence have been grouped using the Japanese
Metabolic Syndrome criteria [7, 18, 20–22]. It is there-
fore important to examine the association between apo
B-48 and metabolic parameters in other populations.
The metabolic aberrations leading to an accumulation
of chylomicron remnants in MetS are unclear, but studies
in animal models and insulin resistant subjects suggest
exaggerated rates of constituent biosynthesis as a conse-
quence of intestinal hypertrophy [23]; decreased lipolysis
because of reduced expression of endothelial lipoprotein
lipase [24] and thereafter, lower rates of receptor medi-
ated endocytosis post-hydrolysis contribute that collect-
ively results in increased vascular exposure.
Plasma triglyceride is commonly utilized as a marker
of postprandial lipaemia and indeed fasting levels have
been reported to correlate with fasting apo B-48 concen-
tration [18, 21, 22]. However, plasma triglyceride princi-
pally reflects the lipolytic cascade and is by extension less
indicative of accumulation of post-hydrolyzed atherogenic
remnants. Greater plasma abundance of triglyceride is
commonly associated with reduced plasma concentration
of HDL cholesterol. The latter reflects principally, de-
creased shedding of surface phospholipids and cholesterol
from triglyceride rich lipoproteins during lipolysis and
genesis of nascent discoidal HDL lipoproteins. In MetS,
heightened plasma triglyceride and/or low HDL choles-
terol may be associated with an accumulation in plasma of
atherogenic chylomicron remnants, however neither
measure are equivocal surrogate markers of remnant
homeostasis per se.
Apo B-48 is produced exclusively by absorptive cells of
the small intestine and is an obligatory moiety of nascent
chylomicrons. In normolipidemic subjects with coronary
artery disease and in subjects with familial hypercholes-
terolemia, apo B-48 is markedly elevated despite other-
wise normal levels of plasma triglyceride [25, 26]. The
plasma abundance of small dense chylomicrons in
Caucasian subjects with MetS has not been previously
reported. Moreover, altered chylomicron homeostasis
in MetS may be associated with one or more of the
MetS components, however this has not been directly
considered. This study reports on associations of fasting
apo B-48 with metabolic and anthropometric measures
in Caucasian men and women.
Methods
Subjects
Two hundred and fifteen Australians with European an-
cestry were sampled randomly from a larger cross sec-
tional study investigating the relationship between
serum vitamin D, bioactive calcium, parathyroid hor-
mone homeostasis and cognitive performance conducted
at our institute in 2011 [27]. An additional exclusion cri-
teria was used for the present study to exclude subjects
on lipid lowering medication. MetS criteria was based
on the new harmonising criteria of Alberti et al. [28]. All
participants have given written informed consent prior
participating in the study. The study has been approved
by the Curtin University Human Research Ethics Com-
mittee (HR97/2011) and was performed in accordance
to Declaration of Helsinki.
Anthropometric measurements
After having fasted for at least 8 h, prior to fasting blood
collection, a range of anthropometric measurements
were performed. Body weight was measured after voiding,
with participants wearing limited clothing on a digital
balance and recorded to the nearest 100 g. Standing
height was measured using a portable stadiometer fixed
to the wall, without shoes and recorded to the nearest
0.1 cm. Waist circumference and ratio was measured
and calculated as described by Norton and Olds [29].
Sagittal abdominal diameter (SAD) was measured by
using an abdominal calliper while the participants were
in a standing position. The SAD was measured as the
distance between the largest point of abdomen and the
back at the end of normal expiration. Blood pressure
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will be assessed using a semi-automatic (arm cuff) blood
pressure monitor (Omron, Vernon Hills, IL) in supine
position. All measurements were done by a certified
anthropometrist.
Lipid, insulin and glucose assays
Fasting serum samples were collected by low-speed
centrifugation of serum separator Vacutainer™ tubes
(Becton Dickinson, Franklin Lakes, NJ, USA) that were
left to clot for 30 min. All samples were then either
analysed immediately or stored at −80 °C prior to ana-
lysis. Fasting serum triglyceride, cholesterol and glucose
were determined by Pathwest Laboratories using their
routine automated procedures on an Architect c1600
analyser. Serum triglyceride, total cholesterol, HDL
cholesterol and glucose concentration were measured
by using specific enzyme-based colorimetric reagents
(Abbott Diagnostics, Abbott Laboratories, Abbott Park,
USA; CV <2 %). LDL cholesterol was estimated by
using a modified version of Friedewald formula [30].
Non-HDL cholesterol concentration was calculated as
the difference between serum total cholesterol and
HDL cholesterol concentration. Insulin level was deter-
mined by using the Mercodia insulin ELISA kit (Mercodia
AB, Uppsala, Sweden) according to the manufacturer’s in-
structions. Insulin resistance was assessed by calculation
of HOMA-IR score [31].
Apo B-48 determination
Chylomicron concentration was measured by determining
apo B-48 concentration. Apo B-48 is the major structural
protein for chylomicron assembly and it is not inter-
changeable [32]. Apo B-48 concentration was measured
by using a commercial sandwich ELISA method using a
monoclonal antibody raised against the C-terminal region
of apo B-48 (Shibayagi Human apo B-48 ELISA Kit,
Ishihara, Shibukawa, Japan) according to the manufac-
turer’s instructions. The details of the validation
method refers to Kinoshita et al. [33].
Statistical analysis
All data were analysed using SPSS version 21 (SPSS Inc.,
Chicago, USA). The results are all presented in the
tables as mean values ± standard error (SE) for normally
distributed data and median (25th and 75th interquartile
range) if the data was skewed. Data that were not normally
distributed were natural log transformed when necessary.
Statistical significance was assessed using Independent-
samples T test, Mann-Whitney test (between 2 groups)
and ANOVA (3 groups or more). Post-hoc comparison
between each group was assessed using Bonferroni test.
To assess the significant difference in apo B-48 between
the MetS and no-MetS group, GLM univariate were used.
Spearman correlations were computed to assess the
association between parameters. The strength of associ-
ation between apo B-48 and a range of anthropometric
and metabolic determinants adjusted for age and gender
were calculated by using Z score derived regression coeffi-
cient between apo B-48 and other variables. Regression
coefficient denotes the standard deviation change in
apoB-48, as a result of 1 standard deviation change in the
variable. A p value < 0.05 was considered significant.
Results
Subject characteristics
The subject characteristics are shown in Table 1. The
median age of the whole subjects was 62 years. Subjects
with MetS were older and had higher anthropometric
measures related to overweight (BMI, waist circumfer-
ence, WHR and SAD) and were more likely to be dyslip-
idemic (high triglyceride and/or low HDL cholesterol).
Subjects with MetS exhibited a higher non-HDL chol-
esterol concentration than those without MetS, but no
significant differences in total cholesterol or LDL choles-
terol concentration were observed in the MetS group.
They were also more insulin resistant than those without
MetS group.
Apo B-48, anthropometric and lipid parameters in MetS
The median serum apo B-48 concentration for the whole
group was 4.8 μg/mL (3.4–7.9) (Table 1). Subjects with
MetS exhibited a 40 % greater apo B-48 concentration
than those without MetS (Table 2; P < 0.01). The differ-
ence between groups remained significant following ad-
justment for age and gender (Table 2). In subjects not
classified as having MetS, the concentration of apo B-48
did not appear to be affected by the presence of 0, 1 or 2
MetS components.
The association between fasting apo B-48 and the
range of outcome measures was examined in all subjects
and also after grouping based on the presence of MetS.
When examined on the whole group, apo B-48 concen-
tration was found to correlate with triglyceride (r = 0.445,
p < 0.0005), non-HDL (r = 0.28, p < 0.0005) and HDL chol-
esterol concentrations (r = −0.272, p < 0.0005) (Table 3).
Weak correlations were observed between apo B-48 con-
centration both LDL cholesterol (r = 0.191, p = 0.005) and
total cholesterol (r = 0.14, p = 0.042). Apo B-48 concentra-
tion was also weakly associated with waist circumference
and WHR (r = 0.162, P = 0.017 and r = 0.178, P = 0.009).
However no association was observed between apo B-48
and either insulin concentration, or HOMA-IR level in all
subjects.
When grouped based on MetS status, subjects with
MetS exhibited an enhanced association of apo B-48
with triglyceride, total- (r = 0.618, p < 0.0005), non-HDL
(r = 0.595, p < 0.0005) and LDL cholesterol (r = 0.576,
p < 0.0005) than those without MetS (Table 2). However
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a negative association with HDL cholesterol concentra-
tion and apo B-48 was only observed in subjects who
did not exhibit MetS. Waist circumference was inversely
correlated with apo B-48 in the MetS group.
Since apo B-48 concentration was associated with age,
we then assessed the association with correcting for age
and gender (Table 4). We observed a minor enhancement
in the association between apo B-48 and triglyceride con-
centration in both groups. The magnitude of association
between apo B-48 and several cholesterol profiles (total
cholesterol, non-HDL and LDL cholesterol) was greater in
the MetS group compared to the no MetS group. How-
ever the contribution of those variables on the variability
of apo B-48 was less than 40 %. We also observed that in
the MetS group, apo B-48 was inversely associated with
BMI and insulin. To assess the contribution of the lipid
variables strongly associated with apo B-48 concentration,
we combined the triglyceride and non-HDL cholesterol in
Table 2 Concentration of apo B-48 according to MetS and in
different cumulative number of MetS components
Presence of MetS N Geometric mean (95 % CI) (μg/mL)
No-Mets 175 4.7 (4.3–5.2)
MetS 40 6.6 (5.4–8.0)
P = 0.001*
MetS components
0 37 4.7 (3.8–5.9)a
1 69 4.7 (4–5.6)a
2 69 4.7 (4.1–5.3)a
≥3 40 6.6 (5.4–8)b
P = 0.004*
*p value after adjusting for age and gender
Different letters (a and b) indicate significant differences
Table 1 Subject characteristics
Characteristics Total (n = 215) No-MetS (n = 175) MetS (n = 40)
Gender (Male/Female) 68/147 46/129 22/18
Age (years) 62 (56–69) 62 (56–68) 66 (59–71)*
BMI (kg/m2) 26.3 ± 0.3 25.5 ± 0.3 29.9 ± 0.6**
Waist circumference (cm) 87.1 ± 0.9 84.1 ± 1 100.3 ± 1.4**
WHR 0.83 ± 0.01 0.81 ± 0.01 0.92 ± 0.01**
SAD (cm) 24.7 ± 0.3 23.6 ± 0.3 29.3 ± 0.5**
Systolic BP (mmHg) 141 ± 1 139 ± 2 150 ± 3**
Diastolic BP (mmHg) 83 ± 1 82 ± 1 85 ± 2
Triglyceride (mmol/L) 1.1 ± 0.03 1 ± 0.03 1.7 ± 0.1**
Total chol (mmol/L) 5.4 ± 0.1 5.4 ± 0.1 5.5 ± 0.2
LDL chol (mmol/L) 3.3 ± 0.1 3.3 ± 0.1 3.5 ± 0.1
HDL chol (mmol/L) 1.5 ± 0.03 1.6 ± 0.03 1.2 ± 0.03**
Non-HDL chol (mmol/L) 3.9 ± 0.1 3.8 ± 0.1 4.3 ± 0.2**
Glucose (mmol/L) 5.1 (4.8–5.4) 5.1 (4.8–5.3) 5.6 (5.3–5.9)**
Insulin (mIU/L) 6 ± 0.2 5.4 ± 0.2 8.8 ± 0.5**
HOMA-IR 1.4 ± 0.1 1.2 ± 0.04 2.2 ± 0.1**
CRP (μg/mL) 2.9 ± 0.2 2.6 ± 0.2 4.3 ± 0.4**
ApoB-48 (μg/mL) 4.8 (3.4–7.9) 4.6 (3.3–7.5) 6.8 (3.9–11.4)**
Metabolic parameters Number of subjects
BMI≥ 25 kg/m2 129 (60 %) 91 (52 %) 38 (95 %)
Large waist 104 (48 %) 68 (39 %) 36 (90 %)
Triglyceride≥ 1.7 mmol/L 31 (14 %) 6 (3 %) 25 (63 %)
Low HDL chol 30 (14 %) 10 (5 %) 20 (50 %)
Hypertension 147 (69 %) 111 (63 %) 36 (92 %)
Fasting glucose≥ 5.6 mmol/L 32 (15 %) 11 (6 %) 21 (53 %)
Mean ± SE for normally distributed variables or median (25th and 75th interquartile range) for non-normally distributed variables; *p < 0.05, **p < 0.01; MetS
compared to no-MetS group. P values between groups were based on independent t-test and Mann-Whitney test for data that is normally and non-normally
distributed data respectively
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Table 3 Non-parametric correlations between anthropometric and lipid/metabolic determinants with Apo B-48 (without adjustment)
Variables Correlation coefficient (p value)
Total (n = 215) No MetS (n = 175) MetS (N = 40)
Triglyceridea 0.445 (p < 0.0005) 0.362 (p < 0.0005) 0.618 (p < 0.0005)
HDL cholesterola −0.272 (p < 0.0005) −0.278 (p < 0.0005) 0.254 (p = 0.113)
Age −0.230 (p = 0.001) −0.262 (p < 0.0005) −0.32 (p = 0.044)
Non-HDL cholesterol 0.28 (p < 0.0005) 0.157 (p = 0.038) 0.595 (p < 0.0005)
WHR 0.178 (p = 0.009) 0.147 (p = 0.053) −0.26 (p = 0.105)
Waist circumferencea 0.162 (p = 0.017) 0.123 (p = 0.106) −0.317 (p = 0.046)
Systolica −0.053 (p = 0.441) −0.106 (p = 0.163) −0.026 (p = 0.875)
LDL cholesterol 0.191 (p = 0.005) 0.094 (p = 0.214) 0.533 (p < 0.0005)
BMI 0.105 (p = 0.123) 0.078 (p = 0.308) −0.27 (p = 0.092)
CRP −0.006 (p = 0.929) −0.073 (p = 0.335) −0.005 (p = 0.977)
Insulin 0.113 (p = 0.1) 0.069 (p = 0.365) −0.158 (p = 0.331)
Glucosea −0.001 (p = 0.984) −0.067 (p = 0.381) −0.222 (p = 0.168)
SAD 0.118 (p = 0.089) 0.06 (p = 0.439) −0.193 (p = 0.247)
HOMA-IR 0.108 (p = 0.113) 0.058 (p = 0.446) −0.201 (p = 0.214)
Diastolica 0.024 (p = 0.729) 0.023 (p = 0.761) −0.066 (p = 0.691)
Cholesterol 0.139 (p = 0.042) 0.021 (p = 0.78) 0.576 (p < 0.0005)
The variables were presented in order based on the strength of association (strong to weak) in the no MetS group. Cells represent Spearman’s Rank correlation
(p-values). Significant correlations are in bold font
aVariable use to determine the presence of MetS
Table 4 The association between Z score of apo B-48 and anthropometric and lipid/metabolic determinants, after adjustment for
age and gender
Variables Regression coefficient based on Z-scores
No MetS MetS
Triglyceridea 0.534 (p < 0.0005, R2 = 0.233) 0.634 (p = 0.001, R2 = 0.436)
Non-HDL cholesterol 0.204 (p = 0.007, R2 = 0.135) 0.546 (p = 0.008, R2 = 0.378)
Glucosea −0.152 (p = 0.208, R2 = 0.105) −0.057 (p = 0.668, R2 = 0.245)
LDL cholesterol 0.149 (p = 0.047, R2 = 0.118) 0.458 (p = 0.039, R2 = 0.327)
Cholesterol 0.144 (p = 0.059, R2 = 0.116) 0.547 (p = 0.009, R2 = 0.374)
HDL cholesterola −0.132 (p = 0.082, R2 = 0.113) 0.154 (p = 0.693, R2 = 0.244)
Waist circumferencea 0.077 (p = 0.336, R2 = 0.102) −0.453 (p = 0.092, R2 = 0.299)
WHR 0.073 (p = 0.453, R2 = 0.1) 0.077 (p = 0.791, R2 = 0.242)
Systolica −0.064 (p = 0.371, R2 = 0.101) 0.06 (p = 0.782, R2 = 0.278)
SAD 0.058 (p = 0.468, R2 = 0.097) −0.420 (p = 0.092, R2 = 0.317)
BMI 0.053 (p = 0.443, R2 = 0.1) −0.603 (p = 0.002, R2 = 0.422)
CRP −0.039 (p = 0.57, R2 = 0.099) −0.153 (p = 0.375, R2 = 0.257)
Insulin 0.014 (p = 0.896, R2 = 0.097) −0.428 (p = 0.049, R2 = 0.319)
Diastolica 0.013 (p = 0.846, R2 = 0.097) −0.165 (p = 0.377, R2 = 0.293)
HOMA-IR −0.005 (p = 0.972, R2 = 0.097) −0.429 (p = 0.069, R2 = 0.308)
Regression coefficient represents the standard deviation change in apoB-48, as a result of 1 standard deviation change in the variable. The variables were presented in
orders based on the strength of association (strong to weak) in the no MetS group. Cells represent: slope estimate (p-value for estimate, R2 for model after adjustment).
Significant associations are in bold font
aVariable use to determine the presence of MetS
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a model adjusted for age and gender. The contribution of
these variables to apo B-48 variability was 23.3 % (R2 =
0.233) in subjects without MetS and 45.1 % (R2 = 0.451) in
those with MetS.
Discussion
In this study, we have examined the importance of
chylomicron remnants, as measured by apo B-48, in
subjects with and without MetS. We report that subjects
with MetS had approximately 40 % higher fasting
concentration of apo B-48 than those without MetS. The
association between the fasting concentration of chylo-
micron remnants and a range of anthropometric and
lipid measures was also examined in subjects with and
without MetS. In the whole group apo B-48 concentra-
tion correlated with fasting triglyceride concentration
and cholesterol profile. In subjects with MetS these
correlations increased in strength but as only 45 % of
the variability in apo B-48 was predicted by the fasting
concentration of triglyceride and non-HDL cholesterol,
we conclude that these are not robust markers of chylo-
micron remnant homeostasis. This conclusion suggests
that there are a significant proportion of subjects with
MetS that have high apo B-48, but normal triglyceride
and cholesterol profile; and hence the importance of apo
B-48 determination in subjects with MetS.
Our observation that subjects with MetS exhibit a
40 % higher fasting concentration of apo B-48 compared
to those without suggests an impairment in chylomicron
metabolism in these subjects. Our findings confirm and
extend those previously reported in a Japanese popula-
tion where it was reported that subjects with MetS had
on average a 34 % or 42 % higher fasting apo B-48 con-
centration (in males and females respectively) compared
to control subjects without MetS [18]. Interestingly we
also observed that elevated apo B-48 concentration was
only observed in subjects who exhibited three or greater
MetS components (and hence exhibited MetS) suggesting
that impaired chylomicron metabolism is reliant on the
altered phenotype of MetS rather than simply being a
consequence of its individual parameters. Chylomicron
metabolism may be impaired in subjects with MetS at the
level of production, lipolysis and/or clearance. Increased
production of apo B-48 particles via elevated availability of
substrate in enterocytes (i.e. due to increased expression
of NPC1L1), increased MTP activity, decreased LPL activ-
ity and reduced LDL receptor and LDL receptor protein
activity have been proposed as a possible mechanism of
the altered chylomicron metabolism [34, 35]. In subjects
with MetS, hepatic overproduction of VLDL has been
reported [36, 37]. Alternatively, exaggerated secretion of
chylomicron particles in MetS may be indicative of intes-
tinal hypertrophy, however this cannot be determined in
this cross sectional study.
In subjects without MetS, there was a relatively weak
correlation of triglyceride with apo B-48, contrasting the
result observed in the MetS group. Since triglyceride
concentration in plasma is mainly contributed by the
triglyceride associated with VLDL particles, the associ-
ation between apo B-48 and triglyceride concentration
suggests a common metabolic defect that is more pro-
nounced in those with MetS, leading to accumulation of
these triglyceride-rich lipoproteins. In order to standardise
for the magnitude of these parameters we also examined
the association between the Z scores of apo B-48 and
anthropometric and lipid/metabolic determinants. This
allowed us to compare the slope of these relationships
when standardised for one standard deviation change in
each parameter, and also to correct for age and gender.
However the slope of the association of Z-scores for most
of these parameters was remarkably low, and although
triglyceride had the highest slope for association with apo
B-48 in the no MetS group, it had a low coefficient of
variation suggesting that triglyceride is a poor surrogate
marker of chylomicron remnant homeostasis. In subjects
with MetS, the slope of the association of Z scores for apo
B-48 with triglyceride and non-HDL cholesterol and the
coefficient of variation were increased, nonetheless these
measures were still not predictive of chylomicron remnant
homeostasis.
In subjects with MetS the elevated triglyceride concen-
tration is suggestive of a lipolytic defect. Although not dir-
ectly measured in this study, subjects with MetS may have
decreased expression of LPL as a consequence of insulin
resistance [24]. A defect in lipolysis would be expected to
promote an increased residency time for TRLs including
chylomicron particles and favour increased lipid exchange
promote accumulation of TRL remnants [38, 39]. In the
plasma compartment, remodelling of lipoproteins involves
the exchange of cholesteryl ester and triglyceride between
triglyceride-rich (chylomicron and hepatic derived) lipo-
proteins and cholesterol-rich lipoproteins (LDL and HDL
particles). Although we have observed an increased circu-
lating concentration of chylomicron remnants in subjects
with MetS this change was not associated with a decrease
in HDL cholesterol concentrations. It seems that other fac-
tors independent to chylomicron metabolism such as HDL
particle instability due to insulin resistance may implicate
the low concentration of HDL cholesterol in MetS [40].
Clearance of chylomicron remnants post hydrolysis is
a highly efficient process that occurs principally via in-
ternalization by LDL receptor and LDL receptor-related
protein 1 after remnants were bound to the HSPG of the
surface of hepatocytes facilitated by apo E [41]. Insulin
resistance has been reported to associate with diminished
remnant clearance by impairing the HSPG structure via
modulation of hepatic SULF2 expression [42] and by al-
tering LDL receptor via PCSK9 [43]. If accumulation of
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chylomicron remnants in MetS occurs principally as a
consequence of impaired lipoprotein binding and/or
depressed receptor expression, then by extension one
would anticipate a strong association with LDL choles-
terol. The findings show that in subjects with MetS, the
association of LDL cholesterol with apo B-48 was
strengthened in comparison to control subjects with
presumably adequate expression of apo B/E receptor.
The findings suggest that decreased expression may
have contributed to an accumulation of chylomicron
remnants in MetS subjects. However as only one-third
of the variability in apo B-48 can be explained by LDL
cholesterol, this does not support the contention that
LDL cholesterol serves as a good surrogate marker of
pro-atherogenic remnant homeostasis in plasma, and
that MetS is not associated with a major defect in high
affinity clearance pathways. The latter may be indicative
of the findings that chylomicron remnants require
greater clusters for apo B/E receptors on the plasma
membrane for internalization, whereas LDL particles
interact with singular receptors. A modest reduction in
receptor expression will therefore have a greater effect
on clearance of chylomicron remnants in comparison
to LDL particles. By extension, LDL cholesterol would
be a poor predictor of remnant homeostasis, particu-
larly if receptor expression is attenuated.
Non HDL cholesterol is defined as the cholesterol asso-
ciated with LDL, VLDL remnants, Lp(a), and chylomicron
remnants and as these represent all the lipoproteins cur-
rently believed to contribute to atheroma development
[44] this measure has been suggested to be included in
routine lipid profiles. In the present study, in addition to
triglyceride, non-HDL cholesterol concentration was also
the major lipid contributor to the variation in apo B-48
concentration in subjects with MetS as shown by the re-
gression analysis. Our observation of a strong association
between concentrations of apo B-48 and non-HDL choles-
terol in subjects with MetS is indicative of the importance
chylomicron remnants to the variability of this measure,
however nonetheless, as with triglyceride concentrations,
there still remains a significant proportion of individuals
who exhibit increased chylomicronemia in the absence of
elevated triglyceride or non-HDL cholesterol concentra-
tions. Furthermore the concentration of HDL cholesterol
was not associated with apo B-48 in either group after
adjustment for age and gender. These findings clearly
demonstrate that HDL cholesterol is not a suitable sur-
rogate to consider chylomicron remnant homeostasis in
Caucasian subjects with MetS.
Substantial evidence has indicated that an altered
chylomicron metabolism might relate to insulin resistance
[45, 46]. Our results show no significant associations
between apo B-48 and either insulin concentrations or
HOMA-IR score, however after adjustment for age and
gender there was a moderate association between insulin
and concentrations, but only in the MetS group. Interest-
ingly Kinoshita et al. [18] reported a strong association
between apo B-48 and HOMA-IR score in both males and
females. However differences in the ethnicity and subject
characteristics may explain this discrepancy. Interestingly
we found that in individuals with MetS, the association
between apo B-48 concentration and some anthropomet-
ric measures was inversely correlated. This could be due
to the diminished LPL activity in adipose tissue caused by
insulin resistance [47]. It seems that apo B-48 concentra-
tion in circulation is associated with the inability to store
fat in adipose tissue in individual with MetS. However this
needs to be clarified in a larger sample size.
The results from this study have extended the findings
from previous studies [18, 21, 22] that have reported the
association between apo B-48 and a range of lipid and
anthropometric measures in Japanese population. Our
observation that apo B-48 concentration correlated with
triglyceride and non-HDL cholesterol in subjects with
MetS may partly explain the increased atherogenic risk
in MetS, however the importance of an increased con-
centration of apo B-48 for atherogenic risk in this group
remains. The present study has several limitations.
Firstly, the cross-sectional nature of the design limits the
causative interpretation between variables. Second, the
older age range of our subjects may not represent the
variation of apo B-48 level in general population. Third,
the relatively small number of subjects with MetS may
overestimate the association.
Conclusion
In summary, our investigation confirms previous reports
that fasting apo B-48 concentration is strongly associated
with triglyceride concentration. Although we observed that
this association was stronger in subjects with MetS there
still remains a significant proportion of the variability in
apo B-48 that is not predicted by components of MetS.
These observations are suggestive of the importance of
assessing TRL remnants, in particular chylomicron rem-
nants in subjects with MetS. These findings suggest that
subjects with MetS exhibit a lipoprotein metabolic defect
the manifestation of which affects the metabolism and
clearance of triglyceride-rich lipoproteins likely contribut-
ing to increased cardiovascular risk.
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